BioNexus Gene Lab
Distributor of composite-industry chemicals with Malaysian genomic screening and an ASEAN cancer-testing license.
Something off on this page? Send us feedback.
Profile
Sells composite-industry chemicals to Southeast Asian manufacturers while operating a smaller Malaysian RNA-screening laboratory and licensing an oncology minimal-residual-disease platform for ASEAN. Chemical trading supplies most revenue, making the company a holding structure rather than a pure-play biotechnology business.
Combines a Malaysian industrial-chemical distributor with a smaller RNA-based screening laboratory and an ASEAN license for an oncology minimal-residual-disease platform. Chemrex buys and resells composite-industry inputs—including resins, fiberglass, adhesives, catalysts and pigments—to Southeast Asian manufacturers, fabricators and contractors. MRNA Scientific analyzes provider-collected blood samples and sends RNA-expression risk reports to referring healthcare providers.
Generates most revenue through chemical trading, with Malaysia its principal market. The licensed VitaGuard platform is intended for cancer residual-disease detection and monitoring after treatment, but reported revenue has so far come from chemical sales and legacy screening. Chemical results depend on supplier availability, working relationships and local demand; laboratory activity relies on sample quality, privacy, quality controls and changing healthcare and laboratory rules. The VitaGuard rollout depends on testing capacity, local regulatory treatment and partner cooperation across ASEAN.
Company facts
Categories
Key statistics
Year to date −61.2% · Average volume (30d) 15.0K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | — | −$0.12 | — | — | $76.2K | — | −4.27% |
| May 15, 2026Q1 FY26 | — | −$0.23 | — | — | $22.8K | — | +3.47% |
| Apr 14, 2026Q1 FY26 | — | −$0.53 | — | — | $483.8K | — | +0.46% |
| Nov 14, 2025Q3 FY25 | — | −$0.39 | — | — | $2.5M | — | +3.31% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $2.3M | $2.5M | $483.8K | $22.8K | $76.2K | |
| Gross profit | $343.5K | $368.0K | $377.7K | −$4.0K | −$22.7K | $13.0K | |
| Operating income | −$618.4K | −$611.3K | −$702.5K | −$1.0M | −$571.4K | −$282.4K | |
| Net income | −$623.3K | −$616.2K | −$709.0K | −$1.0M | −$543.6K | −$286.5K | |
| Diluted EPS | −$0.35 | −$0.34 | −$0.39 | −$0.53 | −$0.22 | −$0.12 | |
| Gross margin | 16.1% | 16.3% | 14.8% | -0.8% | -99.5% | 17.0% | |
| Operating margin | -28.9% | -27.0% | -27.6% | -213.3% | -2,501.7% | -370.8% |
Fiscal years (4-quarter sums)FY21 $13.4M · FY22 $10.9M · FY23 $9.8M · FY24 $9.5M · FY25 $7.4M
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $3.5M · Total debt $198.6K · Total assets $8.7M · Shareholders' equity $7.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 2.42M · Float 1.56M · 64.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Fidelion Diagnostics Pte. Ltd. · other: Greater than 5% holder | 392.3K | 16.23% | Form 4 | Aug 7, 2026 |
| Lee Su-Leng Tan · director, 10 percent owner, officer: Chief Executive Officer | 338.7K | 14.01% | Form 4 | Aug 14, 2026 |
| Set Fui Chong · officer: Chief Financial Officer | 96.8K | 4.00% | Form 4 | Aug 14, 2026 |
| Abdul Hamid Muhammad Azrul Bin · director | 32.3K | 1.33% | Form 4 | Aug 14, 2026 |
| Chee Keong Yap · director | 32.3K | 1.33% | Form 4 | Aug 14, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Natera
Established tumor-informed ctDNA platform for cancer MRD monitoring.
- Guardant Health
Tissue-free liquid-biopsy MRD test for solid-tumor recurrence monitoring.
- Personalis
Tumor-informed MRD testing for treatment response and recurrence tracking.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioNexus Gene Lab | $1.52 | −0.65% | $3.7M | — | — | 1.2 | −96.6% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Personalis | $17.35 | +1.57% | $1.82B | — | — | 26.2 | +30.0% |
| Median | — | — | 18.3 | +37.7% |